SG177309A1 - 3-cyanoquinoline tablet formulations and uses thereof - Google Patents
3-cyanoquinoline tablet formulations and uses thereof Download PDFInfo
- Publication number
- SG177309A1 SG177309A1 SG2011094950A SG2011094950A SG177309A1 SG 177309 A1 SG177309 A1 SG 177309A1 SG 2011094950 A SG2011094950 A SG 2011094950A SG 2011094950 A SG2011094950 A SG 2011094950A SG 177309 A1 SG177309 A1 SG 177309A1
- Authority
- SG
- Singapore
- Prior art keywords
- weight
- composition
- weight percent
- ski
- methoxy
- Prior art date
Links
- QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical compound C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 title abstract description 11
- 239000007916 tablet composition Substances 0.000 title description 7
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims abstract description 174
- 229920002785 Croscarmellose sodium Polymers 0.000 claims abstract description 92
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims abstract description 83
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 82
- 229960001681 croscarmellose sodium Drugs 0.000 claims abstract description 82
- 239000000203 mixture Substances 0.000 claims description 338
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 91
- 239000003826 tablet Substances 0.000 claims description 90
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 81
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 81
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 81
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 81
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 50
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 47
- 229920001983 poloxamer Polymers 0.000 claims description 45
- 229960000502 poloxamer Drugs 0.000 claims description 42
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 30
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 30
- 229940069328 povidone Drugs 0.000 claims description 27
- 235000019359 magnesium stearate Nutrition 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000007941 film coated tablet Substances 0.000 claims 1
- 229940100692 oral suspension Drugs 0.000 claims 1
- 229960003736 bosutinib Drugs 0.000 abstract description 139
- 229920000136 polysorbate Polymers 0.000 abstract description 19
- 239000008247 solid mixture Substances 0.000 abstract description 12
- 238000009472 formulation Methods 0.000 description 184
- 238000004090 dissolution Methods 0.000 description 92
- 229960000913 crospovidone Drugs 0.000 description 64
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 64
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 64
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 34
- 229920000053 polysorbate 80 Polymers 0.000 description 34
- 239000011230 binding agent Substances 0.000 description 33
- 239000007884 disintegrant Substances 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 31
- 239000008186 active pharmaceutical agent Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 25
- 238000005469 granulation Methods 0.000 description 24
- 230000003179 granulation Effects 0.000 description 23
- 239000002245 particle Substances 0.000 description 23
- 239000000080 wetting agent Substances 0.000 description 21
- 239000004615 ingredient Substances 0.000 description 19
- -1 3- cyanoquinoline compound Chemical class 0.000 description 18
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 239000013543 active substance Substances 0.000 description 15
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 15
- 238000000576 coating method Methods 0.000 description 14
- 235000019589 hardness Nutrition 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- 239000000945 filler Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 239000000314 lubricant Substances 0.000 description 11
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 9
- 230000032683 aging Effects 0.000 description 9
- BXPOSPOKHGNMEP-UHFFFAOYSA-N bosutinib hydrate Chemical compound O.C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl BXPOSPOKHGNMEP-UHFFFAOYSA-N 0.000 description 9
- 229960005168 croscarmellose Drugs 0.000 description 9
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 9
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 229950008882 polysorbate Drugs 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 229940032147 starch Drugs 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 239000002274 desiccant Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000001301 EGF receptor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229920003080 Povidone K 25 Polymers 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000009505 enteric coating Methods 0.000 description 5
- 239000002702 enteric coating Substances 0.000 description 5
- 239000008141 laxative Substances 0.000 description 5
- 229940125722 laxative agent Drugs 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000009478 high shear granulation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940044519 poloxamer 188 Drugs 0.000 description 4
- 229920001993 poloxamer 188 Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010053155 Epigastric discomfort Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000009837 dry grinding Methods 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 2
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000009490 roller compaction Methods 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 238000001238 wet grinding Methods 0.000 description 2
- XTYSXGHMTNTKFH-BDEHJDMKSA-N (2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate Chemical compound O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 XTYSXGHMTNTKFH-BDEHJDMKSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- ZTKQHJHANLVEBM-UHFFFAOYSA-N 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoic acid Chemical compound C1=2C=C(C)C(NCC)=CC=2OC2=CC(=NCC)C(C)=CC2=C1C1=CC=CC=C1C(O)=O ZTKQHJHANLVEBM-UHFFFAOYSA-N 0.000 description 1
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical group C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 101100172879 Caenorhabditis elegans sec-5 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
- 101150057744 PDGFA gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 101150109894 TGFA gene Proteins 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 201000007637 bowel dysfunction Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003306 cell dissemination Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920003146 methacrylic ester copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940098514 octoxynol-9 Drugs 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 239000000014 opioid analgesic Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000002897 polymer film coating Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- WDXARTMCIRVMAE-UHFFFAOYSA-N quinoline-2-carbonitrile Chemical class C1=CC=CC2=NC(C#N)=CC=C21 WDXARTMCIRVMAE-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220042174 rs141655687 Human genes 0.000 description 1
- 239000008147 saline laxative Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The present invention provides solid compositions comprising a 3-cyanoquinoline, SKI-606, and further comprising croscarmellose sodium, Tween, or both.
Description
3-CYANOQUINOLINE TABLET FORMULATIONS AND USES THEREOF
The present invention relates to formulations of certain cyanoquinoline compounds. In particular, the invention is directed to stable tablets of a 3- cyanoquinoline compound, 4-(2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4- methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile, and further comprising the super-disintegrant croscarmellose sodium, a surfactant polyethylene oxide sorbitan monooleate (polysorbate/Polyoxyethylene sorbitan monooleate (Tween-80™), or both
Certain 3-cyanoquinoline compounds and pharmaceutically-acceptable salts thereof, are protein kinase inhibitors and possess anti-tumor activity and are therefore useful for treating certain disease states, such as cancer, that result, at least in part, from deregulation of this receptor. Receptor tyrosine kinases are important in the transmission of biochemical signals, which initiate cell replication. They are large enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor receptor (EGFR) and an intracellular portion which functions as a kinase to phosphorylate tyrosine amino acids in proteins and hence to influence cell proliferation. Various classes of receptor tyrosine kinases are known (Wilks, Advances in Cancer Research, 1993, 60, 43-73) based on families of growth factors, which bind to different receptor tyrosine kinases. The classification includes Class | receptor tyrosine kinases comprising the EGFR family of receptor tyrosine kinases such as the EGFR, TGFa, Neu and erbB receptors, Class Il receptor tyrosine kinases comprising the insulin family of receptor tyrosine kinases such as the insulin and IGFI receptors and insulin-related receptor (IRR) and Class Ill receptor tyrosine kinases comprising the platelet-derived growth factor (PDGF) family of receptor tyrosine kinases such as the PDGFa, PDGF and colony-stimulating factor 1 (CSF1) receptors.
It is also known that certain tyrosine kinases belong to a class of non- receptor tyrosine kinases which are located intracellularly and are involved in the transmission of biochemical signals such as those that influence tumor cell motility, dissemination and invasiveness and subsequently metastatic tumor growth (Ulkich et al., Cell, 1990, 61, 203-212, Bolen et al., FASEB J., 1992, 6, 3403-3409, Brickell et al.,
Critical Reviews in Oncogenesis, 1992, 3, 401-406, Bohlen et al., Oncogene, 1993, 8 2025-2031, Courtneidge et al., Semin. Cancer Biol., 1994, 5, 239-246, Lauffenburger et al., Cell, 1996, 84, 359-369, Hanks et al., BioEssays, 1996, 19, 137-145, Parsons et al.,
Current Opinion in Cell Biology, 1997, 9, 187-192, Brown et al., Biochimica et
Biophysica Acta, 1996, 1287, 121-149 and Schlaepfer et al., Progress in Biophysics and
Molecular Biology, 1999, 71, 435-478). Various classes of non-receptor tyrosine kinases are known including the Src-family such as the Src, Lyn and Yes tyrosine kinases, the
Abl family such as Abl and Arg and the Jak family such as Jak 1 and Tyk 2.
The 3-cyanoquinoline compound 4-(2,4-dichloro-5-methoxy-phenylamino)- 6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile, also referred to as SKI-606, or bosutinib, is a weak base with an intrinsic solubility of approximately 0.06 pg/mL at pH 8.0. Below pH 8, the solubility of the compound SKI-606 increases exponentially with decreasing pH due to ionization. However, degradation of SKI-606 was observed at low pH aqueous solution (pH 3 and below) through hydrolysis, although the compound is relatively stable at pH higher than 5.
Some problems with existing solid formulations of 3-cyanoquinolines include variable dissolution, which appears to depend on the active pharmaceutical ingredient’s (API) particle size. Contrary to the norm, the smaller API (Dgo~20 microns) in the PIII formulation appeared to retard dissolution, under similar processing conditions used for the larger API (Dgo~40 microns), as a result failing dissolution specification. This was observed more so with larger tablets (higher strength).
In addition, accelerated dissolution characteristic of formulations after aging/storage was also observed at early timepoints (small yet significant shifts on in dissolution on aging at both room temperature and under accelerated conditions).
Results are presented in two dissolution methods: the 0.1 N HCI method and the
CTAB/pH 5 acetate method, further discussed below The latter method was selected to better show a dissolution profile at timepoints up to 30 minutes, as the 0.1 N HCI method was found to release all drug within the first 10-20 minutes.
It would therefore be desirable to provide a stable, solid formulations of 3- cyanoquinoline compounds, such as 4-(2,4-dichloro-5-methoxy-phenylamino)-6- methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile, which is resistant to API particle size variation, and which is more stable during aging and storage, for use in patients.
Two innovative techniques disclosed herein: Changing the disintegrant type (and disintegrant ratio) to improve dissolution and stability properties; and replacing poloxamer with liquid surfactants like polyethylene oxide sorbitan monooleate (polysorbate/Polyoxyethylene sorbitan monooleate (Tween-80)), also to improve dissolution and stability properties.
In a first embodiment, the present invention provides pharmaceutically acceptable solid compositions of 3-cyanoquinolines comprising 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile. In certain embodiments, such solid compositions are provided as a tablet.
In some embodiments, the present invention provides a unit dosage form comprising 4- (2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)- propoxy]-quinoline-3-carbonitrile.
The present invention provides a pharmaceutically acceptable composition comprising: (a) 20-80, or 30-80 weight percent of 4-(2,4-dichloro-5-methoxy- phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile; and (b) 0.1-20 weight percent of one or more wetting agents, as intragranular components, based on the weight of the composition.
The present invention provides a pharmaceutically acceptable composition comprising: (a) 25-80, or 30-80 weight percent of 4-(2,4-dichloro-5-methoxy-phenylamino)-6- methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile; and (b) 0.1-20 weight percent of one or more wetting agents, as an intragranular component, based on the weight of the composition, wherein the intragranular components of the composition further comprise 82.5 weight percent of the composition and the extragranular components comprise 17.5 weight percent of the composition.
The present invention provides a pharmaceutically acceptable composition comprising: intragranular components (a) 25-80, or 30-80 weight percent of 4-(2,4- dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]- quinoline-3-carbonitrile; (b) 0.1-5.0 weight percent of one or more binders; (c) 1-25 weight percent of one or more fillers; (d) 0.1-5 weight percent of one or more disintegrants, (e) 0.1-5 weight percent of one or more wetting agents, based on the weight of the composition; and extragranular components (f) 1-25 weight percent of one or more fillers; and (g) 0.1-5 weight percent of one or more lubricants, based on the weight of the composition.
The present invention provides a pharmaceutically acceptable composition comprising: intragranular components (a) 25-80, or 30-80 weight percent of 4-(2,4- dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]- quinoline-3-carbonitrile; (b) 0.5-5.0 weight percent of povidone; (c) 1-25 weight percent of microcrystalline cellulose; (d) 0.2-5 weight percent of croscarmellose sodium, (e) 0.5- 5 weight percent of poloxamer, based on the weight of the composition; and extragranular components (f) 1-25 weight percent of microcrystalline cellulose; and (g) 0.5-5 weight percent of magnesium stearate, based on the weight of the composition.
The present invention provides a pharmaceutically acceptable composition comprising: intragranular components (a) about 69 weight percent of 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile; (b) about 2 weight percent of povidone; (c¢) about 6.5 weight percent of microcrystalline cellulose; (d) about 2 weight percent of croscarmellose sodium; (e) about 3 weight percent of poloxamer, based on the weight of the composition; and extragranular components (f) about 15 weight percent of microcrystalline cellulose; and (g) about 0.5 weight percent of magnesium stearate, based on the weight of the composition.
The present invention provides a fast dissolving pharmaceutically acceptable composition comprising: intragranular components (a) 25-80, or 30-80 weight percent of 4-(2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)- propoxy]-quinoline-3-carbonitrile; (b) 0.5-5.0 weight percent of one or more binders; (c)
1-25 weight percent of one or more fillers; (d) 0.5-5 weight percent of one or more disintegrants; (e) 0.2-5 weight percent of one or more wetting agents, based on the weight of the composition; and extragranular components (f) 1-25 weight percent of one or more fillers; (g) 0.5-5 weight percent of one or more disintegrants; and (h) 0.5-5 weight percent of one or more lubricants, based on the weight of the composition.
The present invention provides a fast dissolving pharmaceutically acceptable composition comprising: intragranular components (a) 50-80 weight percent of 4-(2,4- dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]- quinoline-3-carbonitrile; (b) 0.5-5.0 weight percent of povidone; (c) 1-25 weight percent of microcrystalline cellulose; (d) 0.5-5 weight percent of croscarmellose sodium, (e) 0.2- 5 weight percent of poloxamer, based on the weight of the composition; and extragranular components (f) 1-25 weight percent of microcrystalline cellulose; (g) 0.5-5 weight percent of croscarmellose sodium; and (h) 0.5-5 weight percent of magnesium stearate, based on the weight of the composition.
The present invention provides a pharmaceutically acceptable composition comprising: intragranular components (a) about 69 weight percent of 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile; (b) about 2 weight percent of povidone; (c) about 6.5 weight percent of microcrystalline cellulose; (d) about 2 weight percent of croscarmellose sodium; (e) about 3 weight percent of poloxamer, based on the weight of the composition; and extragranular components (f) about 15 weight percent of microcrystalline cellulose; (g) about 2 weight percent of croscarmellose sodium; and (h) about 0.5 weight percent of magnesium stearate, based on the weight of the composition.
The present invention provides a pharmaceutically acceptable composition comprising: intragranular components (a) 25-80, or 30-80 weight percent of 4-(2,4- dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]- quinoline-3-carbonitrile; (b) povidone; (c) microcrystalline cellulose; (d) 0.2-5 weight percent of croscarmellose sodium, (e) poloxamer, based on the weight of the composition; and extragranular components (f) microcrystalline cellulose; and (g) magnesium stearate.
The present invention provides a pharmaceutically acceptable composition comprising: intragranular components (a) about 69 weight percent of 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxyl-quinoline-3- carbonitrile; (b) povidone; (c) microcrystalline cellulose; (d) about 2 weight percent of croscarmellose sodium; (e) poloxamer, based on the weight of the composition; and extragranular components (f) microcrystalline cellulose; and (g) magnesium stearate.
The present invention provides a fast dissolving pharmaceutically acceptable composition comprising: intragranular components (a) 50-80 weight percent of 4-(2,4- dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]- quinoline-3-carbonitrile; (b) povidone; (c) microcrystalline cellulose; (d) 0.5-5 weight percent of croscarmellose sodium, (e) poloxamer, based on the weight of the composition; and extragranular components (f) microcrystalline cellulose; (g) 0.5-5 weight percent of croscarmellose sodium; and (h) magnesium stearate, based on the weight of the composition.
The present invention provides a pharmaceutically acceptable composition comprising: intragranular components (a) about 69 weight percent of 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxyl-quinoline-3- carbonitrile; (b) povidone; (c) microcrystalline cellulose; (d) about 2 weight percent of croscarmellose sodium; (e) poloxamer, based on the weight of the composition; and extragranular components (f) microcrystalline cellulose; (g) about 2 weight percent of croscarmellose sodium; and (h) magnesium stearate, based on the weight of the composition.
The present invention further provides a pharmaceutically acceptable compositions, for instance compositions suitable for pediatric use, comprising as low as about 25 weight percent, 20 weight percent, or even 15 weight percent of 4-(2,4- dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]- quinoline-3-carbonitrile, and about 0.25-5 weight percent, 0.5-5 weight percent, 1-3 weight percent, 3 weight percent, 2 weight percent or 1 weight percent croscarmellose sodium as intragranular components, and about .25-5 weight percent, 0.5-5 weight percent, 1-3 weight percent, 3 weight percent, 2 weight percent or 1 weight percent croscarmellose sodium as an extragranular component, with additional intra- and extra-
granular components such as those described above comprising the remaining portions of the composition.
The present invention further provides a pharmaceutically acceptable compositions comprising 4-(2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4- methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile, and about 0.25-5 weight percent, 0.5-5 weight percent, 1-3 weight percent, 3 weight percent, 2 weight percent or 1 weight percent croscarmellose sodium as intragranular components, and about .25-5 weight percent, 0.5-5 weight percent, 1-3 weight percent, 3 weight percent, 2 weight percent or 1 weight percent croscarmellose sodium as an extragranular component, with additional intra- and extra-granular components such as those described above comprising the remaining portions of the composition.
A further embodiment of the invention includes tablets or tablet cores formed by compressing the above granules, wherein said cores are optionally coated by conventional means, for instance with an up to 4 % polymer film coating, said polymer comprised of conventional coating polymers. An exemplary polymer coating is applied using polyvinyl alcohol and PEG 3350 (Opadry red Il and Yellow II)
The present invention also provides a fast dissolving pharmaceutically acceptable solid compositions comprising 4-(2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3- (4-methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile.
The present invention also provides methods of preparing stable, pharmaceutically acceptable solid compositions comprising 4-(2,4-dichloro-5-methoxy- phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile.
The present invention also provides methods for treating cancer comprising administering to a subject an effective amount of a pharmaceutically acceptable solid compositions comprising 4-(2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4- methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile.
The inventive solid compositions of SKI-606 are useful, among other things, for administering to human or animal subjects, including but not limited to pediatric, juvenile, adult and geriatric subjects.
In a second embodiment, the present invention provides a pharmaceutically acceptable composition comprising: (a) 25-80 weight percent of 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile; and (b) 0.1-20 weight percent of one or more wetting agents, as intragranular and or extragranular components, based on the weight of the composition.
The present invention provides a pharmaceutically acceptable composition comprising: intragranular components (a) 25-80 weight percent of 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile; (b) 0.5-5.0 weight percent of one or more binders; (c) 1-25 weight percent of one or more fillers; (d) 0.5-5 weight percent of one or more disintegrants, (e) 0.2-5 weight percent of one or more wetting agents, based on the weight of the composition; and extragranular components (f) 1-25 weight percent of one or more fillers; (g) 0.5-5.0 weight percent of one or more wetting agents; and (h) 0.5-5 weight percent of one or more lubricants, based on the weight of the composition.
The present invention provides a pharmaceutically acceptable composition comprising: intragranular components (a) 50-80 weight percent of 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile; (b) 0.5-5.0 weight percent of povidone; (c) 1-25 weight percent of microcrystalline cellulose; (d) 0.5-5 weight percent of crospovidone; (e) 0.5-5 weight percent of Polyoxyethylene sorbitan monooleate (Tween-80)™, based on the weight of the composition; and extragranular components (f) 1-25 weight percent of microcrystalline cellulose; (g) 0.5-5 weight percent of crospovidone; and (h) 0.1-5 weight percent of magnesium stearate, based on the weight of the composition.
The present invention provides a pharmaceutically acceptable composition comprising: intragranular components (a) about 69 weight percent of 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile; (b) about 2 weight percent of povidone; (c) about 19.5 weight percent of
-0- microcrystalline cellulose; (d) about 3 weight percent of crospovidone, (e) about 1 weight percent of Polyoxyethylene sorbitan monooleate (Tween-80)™, based on the weight of the composition; and extragranular components (f) about 4 weight percent of microcrystalline cellulose; (g) about 1 weight percent of crospovidone and (h) about 0.5 weight percent of magnesium stearate, based on the weight of the composition.
The present invention provides a pharmaceutically acceptable composition comprising: intragranular components (a) about 69 weight percent of 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxyl-quinoline-3- carbonitrile; (b) about 2 weight percent of povidone; (c) about 19.5 weight percent of microcrystalline cellulose; (d) about 3 weight percent of crospovidone, (e) about 1 weight percent of Polyoxyethylene sorbitan monooleate (Tween-80)™, based on the weight of the composition; and extragranular components (f) about 4 weight percent of microcrystalline cellulose; (g) about 1 weight percent of crospovidone and (h) about 0.5 weight percent of magnesium stearate, based on the weight of the composition.
The present invention provides a pharmaceutically acceptable composition comprising: intragranular components (a) about 69 weight percent of 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile; (b) about 2 weight percent of povidone; (c) about 19.5 weight percent of microcrystalline cellulose; (d) about 1 weight percent of crospovidone, (e) about 1 weight percent of Polyoxyethylene sorbitan monooleate (Tween-80)™, based on the weight of the composition; and extragranular components (f) about 4 weight percent of microcrystalline cellulose; (g) about 3 weight percent of crospovidone and (h) about 0.5 weight percent of magnesium stearate, based on the weight of the composition.
The present invention also provides methods of preparing stable, pharmaceutically acceptable solid compositions comprising 4-(2,4-dichloro-5-methoxy- phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile.
The present invention also provides methods for treating cancer comprising administering to a subject an effective amount of a pharmaceutically acceptable solid compositions comprising 4-(2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4- methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile.
The inventive solid compositions of SKI-606 are useful, among other things, for administering to human or animal subjects, including but not limited to pediatric, juvenile, adult and geriatric subjects.
Figure 1 summarizes tablet dissolution rates for SKI-606 formulations comparing different disintegrating agents (croscarmellose sodium versus crospovidone).
Figure 2 summarizes dissolution on accelerated stability for a SKI-606 formulation including crospovidone. There appears to be a significant shift in tablet dissolution especially at early timepoints.
Figure 3 summarizes dissolution on accelerated stability for a SKI-606 formulation including croscarmellose sodium. No shift (compared to Figure 2) is observed in this case.
Figure 4 summarizes effects of varying Intra and Extragranular (IG and EG)
Croscarmellose sodium concentrations in a SKI-606 formulation on tablet dissolution rates.
Figure 5 summarizes effects of varying Intra and Extragranular (IG and EG)
Crospovidone concentration in a SKI-606 formulation on tablet dissolution rates. A wider dissolution is observed here showing strong concentration dependency of dissolution on ratios of Crospovidone. The formulation containing API of DO0 appears to be markedly different in dissolution from the rest containing API of D90= 40 or 60 microns.
Figure 6 summarizes effects of active pharmaceutical ingredient (API) particle size on Dissolution for Crospovidone containing SKI-606 Formulation containing 2% binder, and 2% intragranular and extragranular disintegrant.
Figure 7A and B summarizes the lack of effect of API particle size in both
CTAB/acetate and 0.1 N HCI medias for the croscarmellose sodium based SKI-606 formulations. The CTAB/acetate media was considered a more discriminating media than the 0.1 N HCI. Compare this to Figure 9A and B that clearly show the disparate effect of API particle size on tablet dissolution in a Crospovidone based tablet formulation.
Figure 8 summarizes the lack of dissolution dependency of croscarmellose based SKI-606 formulations (Runs A, B and C) on tablet hardness within a range of 120-190 N thus attesting to the dissolution robustness of the formulation. Hardness of a tablet may routinely need to be modified in a manufacturing setting and this formulation clearly offers that ability to do so.
Figure 9A and B summarizes effect of API particle size on tablet (100 and 500 mg strengths) dissolution for Crospovidone based formulations in 0.1 N HCI. Compare and contrast this to Figure 7A and B that do not show this dependency.
Figure 10 summarizes upward shift in tablet dissolution a 500 mg Crospovidone based SKI-606 formulation on open dish accelerated stability upto 2 weeks. Dissolution data is shown for 2 formulations with varying binder percentages and disintegrant ratios.
Significant dissolution differences are observed early on during tablet dissolution for both batches, indicating a lack of dissolution reproducibility on accelerated stability.
Compare and contrast this to croscarmellose sodium based formulation in Figure 11 that does not show any differences on stability
Figure 11 summarizes the lack of any dissolution shift of croscarmellose sodium (CCS) based formulation on stability under similar conditions as the Crospovidone (CPV) batches in Figure 10
Figure 12 Shows additional dissolution shift data for Crospovidone (CPV) SKI- 606 formulation in 0.1 N HCI under accelerated aging conditions for 500 and 100 mg strength tablets. A consistent upward trend is observed for both the strengths in 0.1 N
HCI.
Figure 13 summarizes comparative dissolution profiles for SKI-606 formulations with varying concentrations of a wetting agent (poloxamer). It is observed that poloxamer has the unexpected effect of decreasing tablet dissolution in a concentration dependent manner.
Figure 14 summarizes effects of wetting agent on granule dissolution in SKI-606 formulations. This effect shows that increases in poloxamer concentration resulted in increase in granule dissolution.
Figure 15 summarizes effects of accelerated aging uto 6 weeks open dish conditions at both 40 deg C and 40 deg C/75% RH for the SKI-606 formulations containing Polyoxyethylene sorbitan monooleate (Tween-80) as a wetting agent (API
Dg = 38 microns).It is observed that there appears to be negligible shift even under the rigorous stability conditions in an open dish.
Figure 16 summarizes effects of accelerated aging uto 6 weeks open dish conditions at both 40 deg C and 40 deg C/75% RH for the SKI-606 formulations containing Polyoxyethylene sorbitan monooleate (Tween-80) as a wetting agent (API
Dgo = 18 microns).It is observed that there appears to be negligible shift even under the rigorous stability conditions in an open dish.
Figure 17 summarizes the lack of effect of API particle size on tablet dissolution in an SKI-606 formulation containing Polyoxyethylene sorbitan monooleate (Tween-80).
Figure 18 summarizes dissolution on accelerated stability in bottles with desiccant for the 500 mg strength croscarmellose based formulation (2% binder and 2% intra and extragranular CCS) 500 mg coated in Bottles with Desiccant. There is no shift in dissolution observed at 6M at 40Deg C/75% RH.
Figure 19 summarizes dissolution on accelerated stability in bottles without desiccant for the 500 mg strength croscarmellose based formulation (2% binder and 2% intra and extragranular CCS) 500 mg coated in Bottles with Desiccant. There is very little shift in dissolution observed at 6M at 40Deg C/75% RH
Figure 20 summarizes dissolution on accelerated stability in bottles with desiccant for the 500 mg strength croscarmellose based formulation (2% binder and 2% intra and extragranular CCS) 100 mg coated in Bottles with Desiccant. There is no shift in dissolution observed at 6M at 40Deg C/75% RH.
Figure 21A summarizes Scale-up (100 Kg) batch dissolution stability in Bottles with desiccant. There is minimal to no shift in dissolution on stability in CTAB/acetate buffer (A) and no shift in 0.1 N HCI (B).
1. Definitions:
As used herein, an “effective amount” of a compound or pharmaceutically acceptable composition can achieve a desired therapeutic and/or prophylactic effect. In some embodiments, an “effective amount” is at least a minimal amount of a compound, or composition containing a compound, which is sufficient for treating one or more symptoms of a disorder or condition associated with modulation of protein tyrosine kinases. In certain embodiments, an “effective amount” of a compound, or composition containing a compound, is sufficient for treating symptoms associated with, a disease associated with an aberrant tyrosine kinase receptor (e.g. cancer, including malignant and benign tumor growths).
The term “subject”, as used herein, means a mammal and includes human and animal subjects, such as domestic animals (e.g., horses, dogs, cats, etc.).
The terms “suffer” or “suffering” as used herein refers to one or more conditions that a patient has been diagnosed with, or is suspected to have.
The terms “treat” or “treating,” as used herein, refers to partially or completely alleviating, inhibiting, delaying onset of, preventing, ameliorating and/or relieving a disorder or condition, or one or more symptoms of the disorder or condition. “Therapeutically active agent” or “active agent” refers to a substance, including a biologically active substance, that is useful for therapy (e.g., human therapy, veterinary therapy), including prophylactic and therapeutic treatment. Therapeutically active agents include organic molecules that are drug compounds, peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoprotein, mucoprotein, lipoprotein, synthetic polypeptide or protein, small molecules linked to a protein, glycoprotein, steroid, nucleic acid, DNA, RNA, nucleotide, nucleoside, oligonucleotides, antisense oligonucleotides, lipid, hormone, and vitamin.
Therapeutically active agents include any substance used as a medicine for treatment, prevention, delay, reduction or amelioration of a disease, condition, or disorder. Among therapeutically active agents useful in the formulations of the present invention are opioid receptor antagonist compounds, opioid analgesic compounds, and the like.
Further detailed description of compounds useful as therapeutically active agents is provided below. A therapeutically active agent includes a compound that increases the effect or effectiveness of a second compound, for example, by enhancing potency or reducing adverse effects of a second compound.
The expression “unit dosage form” as used herein refers to a physically discrete unit of inventive formulation appropriate for the subject to be treated. It will be understood, however, that the total daily usage of the compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular subject or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of specific active agent employed; specific composition employed; age, body weight, general health, sex and diet of the subject; time of administration, and rate of excretion of the specific active agent employed; duration of the treatment; drugs and/or additional therapies used in combination or coincidental with specific compound(s) employed, and like factors well known in the medical arts.
Briefly, "dry blend" materials are physically blended together before filling capsules or compressing tablets. See, Handbook of Pharmaceutical Granulation
Technology, 1997, Dilip Parikh, Marcel Dekker, Inc. ISBN 0-8247-9882-1, page 309.
In dry granulation (slugging or roller compaction) intragranular materials are blended to prepare slugs or roller compaction. Material is milled and blended with extragranular materials followed by capsule filling or tablet 20 compression. Wet granulation entails blending intragranular materials. Wet granulate the blend with water, with or without a binder, (using high sheer, low sheer granulators) and dry (using temperatures up to 100°
C). Material is milled and blended with extragranular materials followed by capsule filling or tablet compression. See, 25 Handbook of Pharmaceutical Granulation Technology, 1997, Dilip Parikh, Marcel Dekker, Inc. ISBN 0-8247-9882-1, pages 338-368. 2. Pharmaceutically Acceptable Compositions and Formulations:
In certain embodiments, pharmaceutically acceptable compositions of the present invention which comprise SKI-606 and one or more other excipients, such as, for example, one or more binders, carriers, viscosity modifying and suspending agents, wetting agents, wetting agents, sweeteners, pH modifying agents, flavoring agents, preservatives and combinations thereof. One skilled in the art will readily appreciate that the category under which a particular component is listed is not intended to be limiting; in some cases a particular component might appropriately fit it more than one category. Also, as will be appreciated, the same component can sometimes perform different functions, or can perform more than one function, in the context of a particular formulation, for example depending upon the amount of the ingredient and/or the presence of other ingredients and/or active compound(s).
In certain embodiments, the present invention provides a pharmaceutically acceptable solid composition comprising: 4-(2,4-dichloro-5-methoxy-phenylamino)-6- methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile, also referred to as SKI-606. SKI-606 is described in U.S. Pat No, 6,297,258, along with methods of preparing SKI-606, as described in U.S. Pat. No. 7, 297,795. SKI-606 has the following structure
Cl Cl
J
H,O (No Nid
NA
SKI-606 Monohydrate and is isolated as a monohydrate. The 3-cyanoquinoline compound, 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxyl-quinoline-3- carbonitrile, is a weak base with an intrinsic solubility of approximately 0.06 ng/mL at pH 8.0. Below pH 8, the solubility of the compound SKI-606 increases exponentially with decreasing pH due to ionization. However, degradation of SKI-606 was observed at low pH aqueous solution through hydrolysis, although the compound is relatively stable at pH higher than 5, when the 4 aminoquinoline group is not ionized.
In certain embodiments, the inventive SKI-606 formulation obviates one or more problems with solid formulations of 3-cyanoquinolines including variable dissolution, which appears to depend on particle size, accelerated dissolution on storage, and limited stability upon storage. The inventive croscarmellose SKI-606 formulations exhibit disintegration times (of 2-7 minutes) faster than comparable SKI-606 formulations employing a conventional disintegrating agent (e.g. crospovidone, disintegration times about 18-20 minutes).
In certain embodiments, the inventive SKI-606 formulation comprises a film coated SKI-606 formulation that is prepared by high shear wet granulation or pan coating. In other embodiments, the film coated SKI-606 tablet formulation is prepared by other conventional coating techniques.
Disintegration times were compared for SKI-606 formulation using a conventional disintegrating agent, crospovidone, and croscarmellose sodium and summarized in
Table 2. The intragranular disintegrant in this case was kept constant at 3 % w/w. The two formulations have markedly different disintegration times, for instance tablet disintegration times (DT) with the 2% extragranular (EG) SKI-606/CCS formulation is only 3.5 minutes as compared to the SKI-606/CPV formulation with a DT of 22 minutes.
Additionally it is also observed that tablet DT is strongly dependent on tablet hardness for all the SKI-606/CPV formulations, whereas no such dependence is observed for the
SKI-606/CCS formulations. For instance, even for the 3% IG and 2% EG SKI-606/CPV formulation, the DT times for the low and the high hardness tablets vary by 14 minutes (range), whereas the SKI-606/CCS formulations only vary by 3.5 minutes. This observation indicates that the SKI-606/CCS formulation was robust with respect to tablet hardness, a significant improvement with respect to tablet manufacturability characteristics of the inventive SKI-606 formulation.
Tablet dissolution of the inventive SKI-606 formulation (see Figure 1) was also carried out in 0.1 N HCI, which revealed that the tablet dissolution was faster for the
SKI-606/CCS formulations at the 10 and 15 minutes at disintegrant concentrations lower than the ones used for SKI-606/CPV formulations. In addition the data also suggested that the lower binder concentrations enhanced dissolution especially at early time points.
In certain embodiments, amounts of croscarmellose sodium (CCS) in the inventive SKI-606 formulation that provide similar dissolution results are as follows: 1.0-2 % w/w intragranular concentration 2. 1-3% w/w extragranular concentration 3. Binder (Povidone concentrations) may also vary from 1-2% w/w.
In certain embodiments, the intragranular component to extragranular component ratio in the inventive SKI-606 formulation was changed from 3:1 to 2:2.
In certain embodiments, one intragranular (IG) component, a filler comprising microcrystalline cellulose (MCC), was transferred from the intragranular portion to the extragranular (EG) component to facilitate faster disintegration times during tabletting in the inventive SKI-606 formulation. The amount of extragranular filler component was increased to 15 weight % from 4 weight %, based on the weight of the SKI-606 formulation.
In certain embodiments, the grade of MCC in the EG component was changed from
Avicel PH101™ to Avicel PH 102™ to facilitate tablet blend flow.
In certain embodiments, contrary to the common observation that reduction in particle size of the API generally causes an increase in rate of dissolution, it was observed that for SKI 606 formulation, decreasing the API particle size tends to lower the dissolution of the formulation when processed in a n identical fashion as the formulation with higher D90 API particle size. Thus it was observed that that the lower the API particle size, the slower the dissolution rate and higher the API particle size- faster the rate of dissolution, as summarized in Figure 6.
In order to maximize dissolution, one possible approach with the existing formulation is to increase the particle size of the drug like SKI-606. To slow down in dissolution an approach is to use API of lower particle size.
In certain embodiments, no change in the poloxamer concentration was made in the inventive SKI-606 formulation to retain in vivo effects when administered to a human or animal subject.
In certain embodiments, the formulation of the present invention can contain one or more non-rate-controlling layers, membranes or coatings. The location of the non- rate-controlling layer in the formulation is not critical. For example, the non-rate- controlling layer may be present between the at least one core and an enteric coating or a rate-controlling mechanism. Alternatively, the non-rate-controlling layer may surround or coat an enteric coating or a rate-controlling mechanism. The non-rate-controlling layer can be made of one or more polymers, as well as, other ingredients known in the art, such as, but not limited to, plasticizers, pigments/opacifiers, etc. Examples of polymers that can be used include, but are not limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, ethylcellulose, polyvinyl alcohol, and polyethylene glycol. Examples of plasticizers that can be used include, but limited to, polyethylene glycol(s), glycerin, triacetin, triethyl citrate, diethyl phthalate and mineral oils. Examples of pigments/opacifiers that can be used include, but are not limited to, water soluble dyes, pigments, and natural products.
In certain embodiments, the formulations of the present invention can also include at least one enteric coating. Any enteric coating can be used in the present invention, including, but not limited to, solutions or dispersions of methacrylic acid and methacrylic ester copolymers, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, ethyl acrylate/methacrylic acid copolymers, cellulose acetate trimellitate, shellac and combinations thereof. Additionally, the enteric coating used in the formulations of the present invention can be formed as a single or multiple layers.
The thickness of the coating can be readily determined by those skilled in the art, but must be sufficient to protect the formulation in the acidic environment of the stomach.
In certain embodiments, solid pharmaceutically acceptable compositions of SKI- 606 were invented, based on replacing one conventional disintegrating agent, crospovidone, with croscarmellose sodium, which unexpectedly resulted improved stability and uniform dissolution rate of the SKI-606 formulation (see Table 1 and
Figures 1-3).
Wetting agents are well known in the art and typically facilitate drug release and absorption. Exemplary wetting agents include poloxamer, polyoxyethylene ethers, polyoxyethylene sorbitan fatty acid esters polyoxyethylene fatty acid esters, polyethylene glycol fatty acid esters, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, polysorbates, cetyl alcohol, glycerol fatty acid esters (e.g., triacetin, glycerol monostearate, and the like), polyoxymethylene stearate, sodium lauryl sulfate, sorbitan fatty acid esters, sucrose fatty acid esters, benzalkonium chloride, polyethoxylated castor oil, and docusate sodium, and the like, and combinations thereof.
In some embodiments, wetting agents include but are not limted to for example
Polysorbate 80™, glycerin, Polysorbate 65™, polysorbate 60™ USP, Polysorbate 40™
USP, Polysorbate 20™ USP, Octoxynol-9, Nonoxynol-10™ USP, Poloxamer 235™,
Poloxamer 188™ USP. In some embodiments, provided wetting agents comprise from about 0.1 weight % to about 5 weight %, about 1.0 weight % to about 4 weight %, or about 3.0 weight % based upon total weight of the formulation. In certain embodiments, the wetting agent is a poloxamer, including but not limited for example Poloxamer 188™ (Lutrol F-68).
Suitable binders (also referred to as “diluents” and/or “fillers”) are known in the art. For example, suitable binders and fillers include but are not limited to starch, dextrin, sucrose, Sorbitol, Sodium Saccharin, Acesulfame potassium, Xylitol,
Aspartame, Mannitol, starch, PVP (polyvinyl pyrrolidone), low molecular weight HPC (hydroxypropyl cellulose), microcrystalline cellulose (MCC), low molecular weight HPMC (hydroxypropyl methylcellulose), low molecular weight carboxymethyl cellulose, ethylcellulose, alginates, gelatin, polyethylene oxide, acacia, dextrin, sucrose, magnesium aluminum silicate, and polymethacrylates. Fillers include agents selected from the group consisting of microcrystalline cellulose, starch, lactitol, lactose, a suitable inorganic calcium salt, sucrose, glucose, mannitol, silicic acid, or a combination thereof.
In some embodiments, binders and fillers comprise from about 1 weight % to about 25% or about 21.5 weight %, based upon total weight of the formulation. In some embodiments, the binder is one or more grades of MCC, including but not limited to
Avicel PH101™ and Avicel PH 102™.
Incorporation of suitable disintegrant(s) into the inventive SKI-606 formulation facilitate dissolution. Suitable disintegrants are known in the art and include but are not limited to, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, sodium carbonate, crospovidone (cross-linked PVP), sodium carboxymethyl starch (sodium starch glycolate), cross-linked sodium carboxymethyl cellulose (croscarmellose), pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum) or a combination thereof. In some embodiments, a disintegrant is crospovidone. In some embodiments, a disintegrant is croscarmellose sodium.
In some embodiments, a suitable lubricant is included in the inventive SKI-606 formulation. Suitable lubricants or glidants include for example stearates, sodium stearyl fumarate and magnesium salts, magnesium stearate. The amount of lubricants used is 0.2-5 weight percent of one or more lubricants, including about 0.5 weight %, based on the weight of the composition. In some embodiments, the lubricant is magnesium stearate.
Addition of one or more preservatives may be particularly useful in compositions that include SKI-606, and may provide protection from degradation and/or from precipitation. Appropriate preservatives are known to those skilled in the art, and include any pharmaceutically acceptable preservative. Conventional preservatives include, but are not limited to sodium benzoate, Propyl parahydroxybenzoate, Sorbic acid, Propylparaben, Methylparaben, Butylated hydroxytoluene, Propionates, Potassium sorbate, Indinavir and combinations thereof. In some embodiments, provided preservatives comprise from about 0.05 weight %, to about 0.25 weight % or about 0.1 %, based upon total weight of the formulation.
Provided compositions may be formulated into a unit dosage form. Such formulations are well known to one of ordinary skill in the art. In certain embodiments, the present invention provides a formulation comprising a solid dosage form as a tablet.
In other embodiments, the present invention provides a solution for oral administration.
In some embodiments, a unit dosage form contains 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, or 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 825 mg, 850 mg, 875 mg, 900 mg, 925 mg, 950 mg, 975 mg, 1000 mg, 1025 mg, 1050 mg, 1075 mg, 1100 mg, 1125 mg, 1150 mg, 1175 mg, 1200 mg, 1225 mg, 1250 mg, 1275 mg, 1300 mg, 1325 mg, 1350 mg, 1375 mg, 1400 mg, 1425 mg, 1450 mg, 1475 mg, 1500 mg of SKI-606.
In some embodiments, a unit dosage form contains between 5 mg and 500 mg, inclusive, or between 10 mg and 450 mg, inclusive, of SKI-606. In some embodiments, a unit dosage form contains 50 mg, 75 mg, 100 mg, 150 mg, 250 mg, 300 mg, or 500 mg. In some embodiments, a unit dosage form contains more than 500 mg of SKI-606.
In some embodiments, the effective dosage of SKI-606 employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 1000 mg/kg of body weight, optionally given in divided doses two to four times a day, or in sustained release form. The total daily dosage is projected to be from about 1 to 1000 mg, preferably from about 2 to 500 mg. Dosage forms suitable for internal use comprise from about 0.5 to 1000 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
In some embodiments, pharmaceutical compositions of SKI-606 from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. In a preferred embodiment, Oral administration of
SKI-606 is preferred.
For the treatment of cancer, the inventive SKI-606 formulations of this invention can be administered in combination with other anti-tumor substances or with radiation therapy. These other substances or radiation treatments can be given at the same or at different times as the compounds of this invention. These combined therapies may affect synergy and result in improved efficacy. For example, the compounds of this invention can be used in combination with mitotic inhibitors such as taxol or vinblastine, alkylating agents such as cisplatin or cyclophosamide, anti-metabolites such as 5- fluorouracil or hydroxyurea, DNA intercalators such as adriamycin or bleomycin, topoisomerase inhibitors such as etoposide or camptothecin, antiangiogenic agents such as angiostatin, and antiestrogens such as tamoxifen.
Based on the results disclosed for SKI-606 and other 3-cyanoquinoline compounds in U.S. Pat. No. 6,297,258, the inventive SKI-606 formulations are useful antineoplastic agents of significant efficacy, which are useful in treating, inhibiting the growth of, or eradicating neoplasms. In particular, the compounds of this invention are useful in treating, inhibiting the growth of, or eradicating neoplasms that express EGFR such as those of the breast, kidney, bladder, mouth, larynx, esophagus, stomach, colon, ovary, or lung. In addition, the compounds of this invention are useful in treating, inhibiting the growth of, or eradicating neoplasms of the breast that express the receptor protein produced by the erbB2 (Her2) oncogene. Based on the results obtained, the compounds of this invention are also useful in the treatment of polycystic kidney disease.
3. Combination Products and Combined Administration:
In certain embodiments, inventive compositions, and formulations thereof, may be administered alone to treat one or more disorders as described herein, or alternatively may be administered in combination with (whether simultaneously or sequentially) one or more other active agents useful to treat one or more disorders as described herein. Thus, an inventive composition, or formulation thereof, can be administered concurrently with, prior to, or subsequent to, one or more active agents.
In certain embodiments, inventive compositions include one or more other active agents in addition to SKI-606 that is not SKI-606. In some embodiments, inventive formulations comprise both another anticancer compound and SKI-606.
The amount of additional active agent(s) present in combination compositions of this invention will typically be no more than the amount that would normally be administered in a composition comprising that active agent as the only therapeutic agent. In certain embodiments of the present invention, the amount of additional active agent will range from about 50% to 100% of the amount normally present in a composition comprising that compound as the only therapeutic agent.
In certain embodiments, inventive formulations may also be used in conjunction with and/or in combination with conventional therapies for gastrointestinal dysfunction to aid in the amelioration of constipation and bowel dysfunction. For example, conventional therapies include, but may not be limited to functional stimulation of the intestinal tract, stool softening agents, laxatives (e.g., diphelymethane laxatives, cathartic laxatives, osmotic laxatives, saline laxatives, etc), bulk forming agents and laxatives, lubricants, intravenous hydration, and nasogastric decompression. 4. Uses and Kits of Inventive Compositions:
Provided compositions, and formulations thereof, are also useful in treatment of conditions including cancers involving angiogenesis, immune suppression, sickle cell anemia, vascular wounds, and retinopathy, treatment of inflammation associated disorders (e.g., irritable bowel syndrome), immune suppression, chronic inflammation.
In still further embodiments, veterinary applications (e.g., treatment of domestic animals, e.g. horse, dogs, cats, etc.) of use of inventive compositions, and formulations thereof, are provided. Thus, use of provided formulations in veterinary applications analogous to those discussed above for human subjects is contemplated.
It will also be appreciated that inventive compositions, and formulations thereof, can be employed in combination therapies, that is, an inventive composition, or formulation thereof, can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. Particular combination therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that therapies employed may achieve a desired effect for the same disorder (for example, a formulation may be administered concurrently with another compound used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects). As used herein, additional therapeutic compounds which are normally administered to treat or prevent a particular disease, or condition, are known as “appropriate for the disease, or condition, being treated”.
In other embodiments, inventive compositions, and formulations thereof, and unit dose forms are useful in preparation of medicaments, including, but not limited to medicaments useful in the treatment of cancer.
Still further encompassed by the invention are pharmaceutical packs and/or kits comprising inventive compositions, and formulations thereof, and a container (e.g., a foil or plastic package, or other suitable container). Optionally instructions for use are additionally provided in such kits.
In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
All features of each of the aspects of the invention apply to all other aspects mutatis mutandis.
Examples 1 and 2: Preparation of Pharmaceutically Acceptable Compositions of
SKI-606
SKI-606 is prepared according to the methods described in detail in one or more of U.S. Pat Nos. 6,297,258 and 7,297,795. An exemplary inventive formulation of SKI- 606 and a comparative SKI-606 formulation are summarized in Table 1.
Table 1. SKI-606 Formulations
Comparative SKI-606
SKI-606 Formulation 1 [formulation
Intragranular Components
SKI-606 monohydrate (equivalent to
SKI-606 free base
Microcrystalline Cellulose (MCC,
Avicel PH101™ 6.5 17.5
Crospovidone (CPV
Croscarmellose Sodium (CCS I 7
Poloxamer 188™ (Lutrol F-68
Povidone (Kollidon 25™
Components
I
Extragranular Components
Microcrystalline Cellulose (MCC,
Avicel 101™ NA 4
Microcrystalline Cellulose (MCC,
Avicel 102™ 15 NA
Croscarmellose Sodium
Components 17.5
Coating (Opadry Il systems I NA-not applicable or not available
Tablets of the 500 mg strength were compressed using the appropriate tooling equipment and the tablets were compressed at low (11-13kp), target (14-16 kp) and high (17-19 kp) hardnesses. These tablets were then evaluated for disintegration time in 0.1 N HCI.
The comparative SKI-606 formulation was prepared by the process of high shear wet granulation, wet milling, fluidized bed drying, dry milling, blending and compression to tablets that are subsequently film coated. This formulation has been associated with high percentage of gastric irritation in fasted individuals.
Disintegration times were compared for SKI-606 formulation using a conventional disintegrating agent, crospovidone, and croscarmellose sodium and summarized in
Table 2. The intragranular disintegrant in this case was kept constant at 3% w/w. The two formulations have markedly different disintegration times, for instance tablet disintegration times (DT) with the 2% extragranular (EG) CCS formulation is only 3.5 minutes as compared to the CPV formulation with DT of 22 minutes. Additionally it is also observed that tablet DT is strongly dependent on tablet hardness for all the CPV formulations, whereas no such dependence is observed for the CCS formulations. For instance, even for the 2% CPV formulation, the DT times for the low and the high hardness tablets vary by 14 minutes, whereas the CCS formulations only vary by 3.5 minutes. This observation points to the fact that the CCS formulation was robust with respect to tablet hardness. This is a significant improvement with respect to tablet manufacturability characteristics, especially since the tablets are meant to be immediate release tablets.
Table 2. Disntegration times for SKI-606 500mg dose formulations employing
Crospovidone versus Croscarmellose sodium as disintegrating agent. (For reference to formulations, refer to Table 2A)
Binder 1%, EG CPV-1% [Binder 1%, EG CPV- [Binder 2%, EG CPV- 5% %
Runt Ruwn2 ~~ Run3
Sec 20sec [20 sec |37 sec |45 sec 5 sec |10 sec |20 sec
Binder 2%, EG [Binder 2%, EG [Binder 2%, EG [Binder 2%, EG
CPV-5% CCS-1% CCS-2 % CPV-1%
Runa ~~ [Run5 ~~ Run6 Run7
Low [TargetiHard [Low [TargetHard [Low [TargetHard [Low [Target [Hard 10 [13 18 mind min [5 min|2 min|3 min [6 min|{16 [30 min 40 min |min min RO [10 25 [30 min |20 sec |min 11 |B0 41 sec [sec sec [sec 35 sec |sec |sec Sec
Where Hard tablets ->16 kp tablet hardness, target tablets- 14-16 kp and Low hardness- 11-13 kp (kp- Kilo Pascals)
Table 2A: Percent composition of Formulations referred to in Table 2
Run Run 3 7
Intragranular Portion
SKI-606 monohydrate equivalent to anhydrous base
Microcrystalline Cellulose (Avicel | 6.5 6.5 5.5 5.5 5.5 5.5 5.5 101™) hagrarwlar Total 00 | 025 | 925 [925 [928 |oEs [oes [ons
Extragranular Portion
Microcrystalline Cellulose (Avicel
Run Run 3 7 ) EEE.
Tablet dissolution of the inventive SKI-606 formulation (see Figure 1) was also carried out in 0.1 N HCI, which revealed that the tablet dissolution was faster for the
CCS formulations at the 10 and 15 minutes at concentrations lower than the ones used for CPV. In addition the data also suggested that the lower binder concentrations enhanced dissolution especially at early time points.
These trials demonstrate that CCS formulation was better from processability point in that granulation endpoint was not reached suddenly unlike CPV formulations- where endpoint was very susceptible to water input, and CCS formulation disintegration time (DT) was less susceptible to tablet hardness. Lowering of binder may correlate to adequate dissolution with CPV.
It is also evident that for the inventive SKI-606 formulation, which included croscarmellose sodium as a disintegrant, the dissolution is not sensitive to API particle size at 15 minutes, as summarized in Table 3. In addition for all IG/EG ranges studied, the only ratio that gave slower dissolution for CCS formulation at 15 minutes is 1%/0 % intra/extragranular disintegrant. For all other levels, release is more than 90%.
Table 3 : Effect of Disintegrant and API Dgy on 500 mg Core Tablet Disintegration and Dissolution
Binder (% wiv)
IG Disintegrant (%
Iw) 3 3 3 3 3 2 1 1
EG dsniegron (4 3 | © | 1 | 1 [0 [0 T | 0]
we) 1 1 1 (min) [for 14-16 kp
Tablets] 18.32 | 15.73 | 2548 | 4.18 | 4.75 [143 | 74 | 23.4 nore Jolson | mo loser | o [or [re] oro min in 0.1 N HCI 67.68 | 50.21 | 23.41 | 94.21 92 97 | 97.2 | 67.6 moines | 0 | ow | | 0 | or [ow] on min in 0.1 N HCI 94 47 97 101
These studies show that the croscarmellose sodium formulations were superior from a manufacturability perspective in that the granulation endpoints were easier to identify (reduced risk of over-granulation); the disintegration times for the croscarmellose sodium formulations were impacted less by tablet hardness; and lowering binder (povidone) concentration results in higher rates of dissolution of CPV formulations as expected due to its influence on rate of tablet disintegration. The change in binder was not deemed necessary for the CCS formulation that shows excellent tablet disintegration times and dissolution regardless of the binder concentration.
The results of extensive experimentation demonstrated that croscarmellose sodium formulations were more robust with respect to variability in drug substance particle size and consistency of dissolution profile for product on stability. Some advantages were seen bychanging the intra to extragranular ratio of microcrystalline cellulose to improve both tablet disintegration times as well as blend flow, and keeping the poloxamer and the binder same as the reference composition.
It is also evident that for the inventive SKI-606 formulation which included croscarmellose sodium as a disintegrant, the dissolution is slower for smaller particle size, as summarized in Tables 2 and 3.
In addition, it was observed that no incompatibilities or degradation were seen at 2 and 4 weeks with either disintegrant at 40° C (dry and wet). Batches on stability studies at 40° C and 40° C /75% RH conditions showed that dissolution shifts observed with CPV, but not with CCS, as summarized in Figures 2 and 3.
Based on the measured data and results, the croscarmellose formulation is seen to provide superior SKI-606 tablet formulations, as API variability effect on dissolution and dissolution shift on stability areboth addressed, while making minimal changes to the formulation (It was thus decided to keep the binder povidone and poloxamer constant at 2% and 3% respectively.) Disintegrant type and the IG/EG disintegrant ratio was changed from 3:1 in clinical to 2:2 (% w/w). Figures 4 and 5 describe the effect on disoolution by changing the intra and extragranular disintegrant ratios for both croscarmellose and Crospovidone respectively.
Example 3: Preparation of Fast Dissolving Pharmaceutically Acceptable
Compositions of SKI-606
SKI-606 is prepared according to the methods described in detail in one or more of U.S. Pat Nos. 6,297,258 and 7,297,795. An exemplary inventive fast dissolving formulation of SKI-606 and a comparative SKI-606 formulation are summarized in Table 4.
Table 4. Exemplary Fast Dissolving SKI-606 Formulation with Croscarmellose sodium .
Fast dissolving SKI- |Comparative SKI-606 606 formulation Formulation
Intragranular
SKI-606 Monohydrate (equivalent to anhydrous SKI-606 free base
Microcrystalline Cellulose (101™
Crospovidone (CPV
Croscarmellose Sodium (CCS 2 INA 00000000
Poloxamer 188 (Lutrol F-68™
Povidone (Kollidon 25™ % Intragranular portion 825 leas 000000
Extragranular
Microcrystalline Cellulose (101™) | ~~ @
Microcrystalline Cellulose (102) 115 ~~ }
Croscarmellose Sodium % Extragranular portion i756 0 bbs 0000000
Coating PB J 00000000
NA-not applicable or not available
The gastric irritation effect of the formulation may be a result of prolonged residence time in the stomach and upper Gl tract. The inventive SKI-606 formulation also provides a relatively fast dissolving salt of the drug that solubilizes faster in the Gl tract. The fast dissolving salts of the drug includes the citrate, succinate, fumarate, Di-
HCI, Di- mesylate, acetate, maleate, tartarate and HCI salts to name a few, providing a SKI-606 formulation useful for dissolving or disintegrating faster within the Gl tract to cause rapid drug dissolution.
A faster disintegrating formulation was prepared by making a few changes to the current formulation. This was done by incorporating the following changes in the formulation: eplacing the disintegrant crospovidone with croscarmellose sodium. This disintegrant acts by a “swelling” action promoting early disintegration times as compared to the “wicking” action promoted disintegration with the crospovidone. It is found to exert a faster disintegrant action at comparable concentrations as the crospovidone.In addition to replacing the disintegrant, an additional change done was the change in the ratio of the microcrystalline cellulose. Microcrystalline cellulose, Avicel PH 101 was reduced intragranularly and increased extragranularly to help improve the disintegrant efficacy. The grade was also changed from Avicel 101 to a larger particle sized 102 to improve blend flow and compressibility. This approach was found to yield faster disintegrating and dissolving tablets, both of which are expected to improve the gastric outcome in the stomach. The inventive SKI-606 formulation is based on this approach.
Example 4: Preparation of Pharmaceutically Acceptable Compositions of SKI-606 as Coated Tablet
SKI-606 is prepared according to the methods described in detail in one or more of U.S. Pat Nos. 6,297,258 and 7,297,795. An exemplary coated tablet from inventive formulation of SKI-606 at two different unit dosages is summarized in Table 5.
Table 5. Coated Tablets of SKI-606 formulation at Different Unit Dosage strengths
Batch Size: 25 Kg
Function | Based | Based on Input/ Input/ Representativ
Ingredient on Intragranula | Dosage Unit Dosage Unit | e tablet r solids (For 500 mg (For 100 mg | Batch core % | portion dose dose Formula wt/wt strength) strength)
J [| of Tt Ton wt/wt t
SKI-606 Active 68.9 | 83.6 500 mg | 100.0 | mg | 17.241 | Kg equivalent to anhydrous base ne cellulose (PH 101)° se Sodium t 188 agent 25
Water ° Solution ree [ET [Emenee 6 0 4
Dry blend and Coating portion:
Table 6. Dry blends and coated SKI-606 formulations.
Function | Based | Input/ Input/ Representative
Ingredient on Dosage Dosage Unit Batch Formula tablet | Unit core Input (500 | Input (100 U | Input Unit % mg) mg) nit wt/wt granulation portion q cellulose (PH 102 2 Q
Sodium ant 0
Stearate 0
Function | Based | Input/ Input/ Representative
Ingredient on Dosage Dosage Unit Batch Formula tablet | Unit core Input (500 | Input (100 U | Input Unit % mg) mg) nit wt/wt o rr rr rr rrr
COATING or rr rr 1
Opadry-Il yellow, | Coating 3.0 NA 4.350 m [0.975 Kg 85F12390 agent 0
Opadry-Il red, 21.75 NA 85F15642 carrier rr rr rr
Towle | [fo [77 [Wes me |68 Kg
The SKI-606 formulation and coated tablets of the SKI-606 formulation were prepared as follows:
MANUFACTURING PROCEDURE
The SKI-606 formulation and coated tablets of the SKI-606 formulation were prepared as follows:
Weighed the following ingredients for a batch size of 25 Kg:
SKI-606 monohydrate 17.241Kg
Microcrystalline cellulose (Avicel PH 101) 1.624 Kg
Croscarmellose sodium 0.5 Kg
Povidone K-25 0.5 Kg
Poloxamer 0.75 Kg 1. Dissolved the Povidone and the poloxamer into the purified water. 2. Added the SKI-606, microcrystalline cellulose (PH 101), and croscarmellose sodium of the intra-granular portion to the high shear granulator and mix for a minimum of 4 minutes, or until uniform. The dry ingredients may be passed through a screen, if necessary, to de-lump prior to pre-blending. 3. While mixing, added the Step 1 solution to the high shear granulator and mix until a suitable granulation is achieved. The water quantity may be adjusted to achieve a satisfactory granulation endpoint if required.
4. The granulation may be passed through a mill or screen, if necessary, to facilitate a uniform granulation before drying. 5. Dried the granulation in a fluid bed dryer until a satisfactory endpoint is reached.
The LOD at this point should be below 3% w/w with a target between 1-1.5 % w/w under test temperature conditions. 6. Passed the dried granulation through a mill equipped with an appropriate sieve or screen to facilitate a satisfactory particle size distribution for blending. Retain a portion of this for Step 10. 7. Added the granulation to a suitable blender. If required, mix the dry sized granulation for a minimum of 5 minutes, or until uniform. 8. Calculate the amounts of extragranular ingredients based on yields obtained of the dried granulation. 9. The dry blend ingredients may be passed through a screen, prior to blending.
Retain a sample of microcrystalline cellulose if required for blending in Step 10.
Add the microcrystalline cellulose and croscarmellose sodium to the mixer and blend for 10 minutes, or until uniform. 10.Added either a portion of granulation from Step 6 or microcrystalline cellulose (PH 102) from Step 9 to the magnesium stearate and mix to form a lubricant pre- blend. Add the lubricant pre-blend to the Step 9 blender and mix for a minimum of 2 minutes, or until uniform. 11.Compress the granulation using appropriate tooling, at adequate hardness
Preparation and Application of Coating Suspension 1. Prior to mixing, the dry color was passed through a screen, if necessary. Using a suitable mixer and tank, to the color coat was added to the purified water and mixed until a satisfactory suspension was formed. The suspension may be sieved through an appropriate screen. 2. 5 Kg of the coating suspension was applied to the bed for a total 3% wt/wt weight gain. This may if required be verified by tablet weight gain.
Table 7: Examples of Coated Tablets of SKI-606 formulation with Crospovidone disintegrant at Different Unit Dosages
Ingredients Qty (%w/w) of Qty/tablet (mg) | Qty/tablet (mg) tablet core for 100 mg for 500 mg dose weight dose tablet tablet
SKI 606 104.17 520.83 monohydrate (Based on 96% assay)
Avicel pH 101 33.52
Poloxamer-188™ 21.74 14.49
Extragranular ingredients 21.74
Avicel pH 101™ 20.29 101.45 stearate
Total Uncoated tablet weight (mg) | 145.0 | 725.0
Opadry Il Yellow 85F12390 at4% ww | 6.04 | = —
Opadry Il Red 85F15642 85F12390 at 30.19 4% wiw
Total tablet weight of coated tablet 755.19 (mg)
The SKI-606 formulation and coated tablets of the SKI-606 formulation were prepared as follows for a batch size of 1 Kg core tablets:
Weighed the following ingredients:
SKI-606 monohydrate 718.49
Microcrystalline cellulose (Avicel PH 101) 46.23 g
Crospovidone 10.0 g
Povidone K-25 20.00g
Poloxamer 188 30.00 g 1.Passed SKI-606, Microcrystalline Cellulose and Crospovidone from step 1 through a 20 mesh screen and ingredients were added to a high shear mixer.
2. Mixed the ingredients in step 2 in a high shear granulator for 2 minutes at low plow speed (Impeller only). 3. Dissolved Poloxamer 188 and Povidone K-25 in Purified water in another mixer.
Used low mixer speed to avoid the generation of foam 4. Set the impeller and chopper speed to low setting. Added the solution from step 4 using a pump to granulate the mix in Step 3. If necessary, when the granulation solution was exhausted, continued mixing for an additional 2- 5 minutes with the chopper and impeller at low speed. Added additional Purified Water if necessary while mixing until the granulation end point is reached. Checked for the desired granulation end point. Record the total amount of water used to granulate and the total mixing time as well as power or torque reading if available. 5. Dried the granulation in a Fluid bed dryer with inlet suggested set value temperature of 70°C £5°C to a suggested L.O.D. range of 1 .5% to 2.5 %. Weighed and recorded yield. 6. Passed the dried granulation through a Comil at low speed (suggested mill speed 700 rpm or below and suggested screen: 20 mesh,). Weighed and recorded yield.
FINAL BLEND: 7. Based on the yield in step 7, calculated the amount of ingredients required for (extra granular) dry addition. 8. Transferred the milled granulation from Step 9 into a suitable size V-blender. 9. Weighed the Microcrystalline cellulose (PH 101), Crospovidone and passed through a 20-mesh screen and add to the V-blender in step 11. Blend for 10 minutes without the intensifier bar activation. 10. Passed Magnesium stearate through a 30-mesh screen and bag blend with an equal portion of granulation of step 12 and added to the V-blender. Blend for 2 minutes without intensifier bar. 11. Weighed and recorded yield.
Compress tablets at known weights and hardnesses and film coated compressed tablets.
In certain embodiments, the inventive SKI-606 formulation obviates one or more problems with solid formulations of 3-cyanoquinolines, namely, variable dissolution and a tendency for certain SKI-606 formulations (see comparative Example) to undergo small yet significant shifts on in dissolution on aging at both room temperature and under accelerated conditions when tested in buffer solution or under acidic conditions, as summarized in Figures 10 and 12. Figure 11 shows the lack of dissolution shift for the croscarmellose formulation. Figure 12 shows the dissolution shifts in existing formulation. The poloxamer 188 in the SKI-606 comparative formulation was responsible for the shift in dissolution observed. Poloxamer though a solid at room temperature tends to undergo liquefaction at and around temperatures near its melting point of 48-52° C. Studies summarized in Figures 13 and 14 revealed that the poloxamer in the Crospovidone based formulation was indeed the reason that the tablets were shifting in dissolution.
In certain embodiments, SKI-606 tablet formulations were prepared with varying amounts of poloxamer, ranging from 0, 1.5, 3, 4.5 and 6% w/w, based on the weight of the SKI-606 formulation. Unexpectedly. it was observed that there existed a clear dependency of tablet dissolution on the percent poloxamer content of the formulation, when tested in 0.1 N HCI. Figure 13 summarizes the effects of varying poloxamer content on tablet dissolution at similar water and binder addition rates in 0.1 N HCI. It is observed that the poloxamer actually appears to retard the release especially at early time points for the tablets tested. Poloxamer appeared to retard initial tablet dissolution at 15 and 30 minutes in a concentration dependent manner. See Table 8.
Varying Poloxamer content % wiw min 222200 2 | 6266 . eo | 5 00 143149
Although the poloxamer in tablets tends to retard dissolution initially, it was found to speed up dissolution on accelerated stability at later timepoints in 0.1 N HCI media as seen in the data summarized in Table 9.
Buffer (Stability Studies) (G) rate (g/min) wiw) (+ -Increase in % dissolution from initial) f47 Iss JO [mia |66 [iM@40DegC +3 1M@40DegC/75%RH |+6 rr 162 |s85 15 [mil |50 = [iM@40DegC |*19 1M@40DegC/75%RH |+22 rr 'M@40DegC [+11 0 ['M@40DegCi75%RH | +31 rr fw es we fa [wWesbwc [+5 [TMeaDwormRA [w
EE
147 |%85 ~~ |60 [imi |38 [IM@40DegC +6 1] [1M@40DegC/75%RH | +14
On accelerated stability, poloxamer causes a dissolution shift in a concentration dependent manner from 0 to 3% w/w. The dissolution shift beyond 3% poloxamer concentration plateaus off with no evident trends. These results verify that the poloxamer can cause dissolution shifts to happen on stability. The poloxamer chains on aging and at accelerated temperatures are believed to become more mobile, and thus instead of holding the granules together in the tablet the mobile polymer chains tends to “soften” the tablets. This could be as a result of granule softening over time as well as increased tendency to disintegrate. Also seen are lowered disintegration times on stability. Once the tablet has disintegrated the granules in the tablet actually show behavior very similar to all known surfactants. Increase in surfactant tends to increase granule dissolution as seen in Figure 14.
This dissolution shift problem was obviated by the inventive SKI-606 formulation, by replacing the wetting agent poloxamer, which also functions as a surfactant, in the formulation. The use of a lower melting point surfactant (one that was liquid at room temperature) could help to address this issue. Polyoxyethylene (20) sorbitan monooleate (Tween™ or polysorbate 80™ i) is one of the commonly used surfactants in use. The concentration of Polyoxyethylene (20) sorbitan monooleate (Polyoxyethylene sorbitan monooleate (Tween-80)™) tested was 1% in place of the 3% poloxamer in the formulation. This was used in the CPV formulation with 3% 1G and 1% EG CPV as the disintegrant. This was deemed acceptable as the dissolution and other manufacturability characteristics tested at this concentration were acceptable. In addition,
Polyoxyethylene sorbitan monooleate (Tween-80)™ is a commonly used pharmaceutically acceptable wetting agent and also functions as a surfactant.
In addition to addressing dissolution shift, testing of the robustness of these formulations with respect to active pharmaceutical ingredient API particle size is desirable. The comparative SKI-606 formulation the API particle size appeared to influence the dissolution i.e. smaller the API particle size, slower the dissolution. With the SKl/Tween-80 formulation, this effect was minimized or negligible (Figure 17) and the SKI-606 formulations comprising the alternative wetting agent Polyoxyethylene sorbitan monooleate (Tween-80)™ were superior in aging (Figures 15 and 16) to the comparative SKI-606 formulation
Examples 11 and 12: Preparation of Pharmaceutically Acceptable Compositions of SKI-606
SKI-606 is prepared according to the methods described in detail in one or more of U.S. Pat Nos. 6,297,258 and 7,297,795. An exemplary inventive formulation of SKI- 606 and a comparative SKI-606 formulation are summarized in Table 10.
Table 10. SKI-606 Formulations oso sop
SKI-606 Comparative SKI-[Surfactant
Formulation 1 606 formulation [Formulation
Intragranular Components hy ha equivalent to SKI-606 base pp Lo le la
MCC, Avicel PH101 6.5 17.5 19.5 ee
CCS NA NA pore 68™™ 3 3 NA een monooleate (Tween -80
Povidone (Kollidon25) Pp ~~ pp hy he he
Components ene LL
MCC, Avicel 101™ NA 4 4 en le da
MCC, Avicel 102™ 15 NA NA
Croscarmellose Sodium ~~ INA ~~ INA
De Ly ha he
Components 17.5 remy hh systems 3
NA-not applicable or not available
Alternative SKI-606 Formulation comprising Polyoxyethylene sorbitan monooleate (Tween-80) as a wetting are summarized in Tables 11-13.
Table 11. Alternate SKI-606 Formulations Comprising Polyoxyethylene sorbitan monooleate (Tween-80) and varying Crospovidone. . Alternate Tween Alternate Tween Alternate Tween
Ingredients formulation formulation formulation % wiw % wiw % wiw
SKI-606 Monohydrate equivalent to SKI-606 base 69 69 69
Microcrystalline Cellulose (MCC, Avicel PH101) 21.5 20.5 18.5
Crospovidone (CPV) 1 2 4
Croscarmellose Sodium (CCS) NA NA NA
Tween-80™ 1 1 1
Povidone (Kollidon 25™) 2 2 2
Weight % Intragranular
Components 94.5 94.5 94.5
Microcrystalline Cellulose (MCC, Avicel 101) 2 3 5
Crospovidone 3 2 0
Magnesium stearate 0.5 0.5 0.5
Weight % Extragranular
Components 5.5 5.5 5.5
Table 12. Alternate SKI-606 Formulations Comprising Varying Polyoxyethylene sorbitan monooleate (Tween-80). . Alternate Tween Alternate Tween Alternate Tween
Ingredients formulation formulation formulation % wiw % wiw % wiw
SKI-606 Monohydrate equivalent to SKI-606 base 69 69 69
Microcrystalline Cellulose (MCC, Avicel PH101) 20 20.25 19.75
Crospovidone (CPV) 3 3 3
Croscarmellose Sodium (CCS) NA NA NA
Tween-80™ 0.5 0.25 0.75
Povidone (Kollidon 25) 2 2 2
Weight % Intragranular
Components 94.5 94.5 94.5
Microcrystalline Cellulose (MCC, Avicel 101) 4 4 4
Crospovidone 1 1 1
Magnesium stearate 0.5 0.5 0.5
Weight % Extragranular
Components 5.5 5.5 5.5
Table 13. Alternate SKI-606 Formulations Comprising Polyoxyethylene sorbitann monooleate (Tween-80) with varying binder concentrations. . Alternate Tween Alternate Tween Alternate Tween
Ingredients formulation formulation formulation % wiw % wiw % wiw
SKI-606 Monohydrate equivalent to SKI-606 base 69 69 69
Microcrystalline Cellulose (MCC, Avicel PH101) 20.5 19.5 18.5
Crospovidone (CPV) 3 3 3
Croscarmellose Sodium (CCS) NA NA NA
Tween-80™ 1 1 1
Povidone (Kollidon 25) 1 2 3
Weight % Intragranular
Components 94.5 94.5 94.5
Microcrystalline Cellulose (MCC, Avicel 101) 4 4 4
Crospovidone 1 1 1
Magnesium stearate 0.5 0.5 0.5
Weight % Extragranular
Components 5.5 5.5 5.5
The comparative SKI-606 formulation was prepared by the process of high shear wet granulation, wet milling, fluidized bed drying, dry milling, blending and compression to tablets that are subsequently film coated.
In certain embodiments, the inventive SKI-606 formulation comprises a film coated SKI-606 formulation that is prepared by high shear wet granulation or pan coating. In other embodiments, the film coated SKI-606 tablet formulation is prepared by other conventional coating techniques.
Claims (20)
1. A pharmaceutically acceptable composition comprising: intragranular components (a) 20-80 weight percent of 4-(2,4-dichloro-5-methoxy-phenylamino)-6- methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile based on the weight of the composition; (b) povidone; (c) microcrystalline cellulose; (d) 0.25-5 weight percent of croscarmellose sodium based on the weight of the composition, (e) poloxamer; and extragranular components (f) microcrystalline cellulose; and (g) magnesium stearate.
2. A pharmaceutically acceptable composition comprising: intragranular components (a) 25-80 weight percent of 4-(2,4-dichloro-5-methoxy-phenylamino)-6- methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile based on the weight of the composition; (b) povidone; (c) microcrystalline cellulose; (d) 0.25-5 weight percent of croscarmellose sodium based on the weight of the composition, (e) poloxamer; and extragranular components (f) microcrystalline cellulose; and (g) magnesium stearate.
3. The composition according to claim 1, wherein the amount of 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile is about 69 weight %, based on the weight of the composition.
4, The composition according to any one of claims 1-3, wherein the amount of croscarmellose sodium is about 1-3 weight %, in the intragranular portion, based on the weight of the composition.
5. The composition according to any one of claims 1-3, wherein the amount of croscarmellose sodium is about 1-3 weight %, in the extragranular portion, based on the weight of the composition.
6. The composition according to claim 1, wherein the amount of povidone is about 2 weight %, based on the weight of the composition.
7. The composition according to claim 1, wherein the amount of microcrystalline cellulose is about 21.5 weight %, based on the weight of the composition.
8. The composition according to claim 7, wherein the amount of microcrystalline cellulose as an intragranular component is about 6.5 weight %, based on the weight of the composition; or the amount of microcrystalline cellulose as an extragranular component is about 15 weight %, based on the weight of the composition; or both.
0. The composition according to claim 1, wherein the amount of poloxamer is about 3 weight %, based on the weight of the composition.
10. The composition according to claim 1, wherein the amount of magnesium stearate is about 0.5 weight %, based on the weight of the composition.
11. A pharmaceutically acceptable composition for oral administration, comprising: intragranular components (a) 25-80 weight percent of 4-(2,4-dichloro-5-methoxy- phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile; (b) 0.5-5.0 weight percent of povidone; (c) 1-25 weight percent of microcrystalline cellulose; (d) 0.5-5 weight percent of croscarmellose sodium; (e) 0.2-5 weight percent of poloxamer, based on the weight of the composition; and extragranular components (f) 1-25 weight percent of microcrystalline cellulose; (g) 0.5-5 weight percent of croscarmellose sodium; and (h) 0.5-5 weight percent of magnesium stearate, based on the weight of the composition of the uncoated/core tablet.
12. The composition according to claim 8, wherein the amount of 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3- carbonitrile is about 69 weight %, based on the weight of the composition.
13. The composition according to claim 11 or 12, wherein the amount of croscarmellose sodium is about 1-3 weight %, in the intragranular portion, based on the weight of the composition.
14. The composition according to claim 11 or 12, wherein the amount of croscarmellose sodium is about 1-3 weight %, in the extragranular portion, based on the weight of the composition.
15. The composition according to claim 11, wherein the amount of povidone is about 2 weight %, based on the weight of the composition; the amount of microcrystalline cellulose is about 21.5 weight %, based on the weight of the composition; the amount of poloxamer is about 3 weight %, based on the weight of the composition; or the amount of magnesium stearate is about 0.5 weight %, based on the weight of the composition.
16. The composition according to claim 15, wherein the amount of microcrystalline cellulose as an intragranular component is about 6.5 weight %, based on the weight of the composition; the amount of microcrystalline cellulose as an extragranular component is about 15 weight %, based on the weight of the composition; or both.
17. A pharmaceutically acceptable composition comprising: intragranular components 25-80 weight percent of 4-(2,4-dichloro-5-methoxy-phenylamino)-6- methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile based on the weight of the composition; and 0.25-5 weight percent of croscarmellose sodium based on the weight of the composition; and extragranular components optionally comprising microcrystalline cellulose; and magnesium stearate.
18. The composition according to claim 1 or 11, in the form of an oral suspension of 4-(2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)- propoxy]-quinoline-3-carbonitrile.
19. The composition according to claim 1 or claim 11, in the form of a wet granulated, film coated tablet, or in the form of a pan coated tablet.
20. A method for treating cancer comprising administering an effective amount of a composition according to claim 1 or claim 11.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22253709P | 2009-07-02 | 2009-07-02 | |
PCT/US2010/040555 WO2011002857A2 (en) | 2009-07-02 | 2010-06-30 | 3-cyanoquinoline tablet formulations and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG177309A1 true SG177309A1 (en) | 2012-02-28 |
Family
ID=42732381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011094950A SG177309A1 (en) | 2009-07-02 | 2010-06-30 | 3-cyanoquinoline tablet formulations and uses thereof |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP2448563A2 (en) |
JP (1) | JP2011012063A (en) |
KR (1) | KR20120046216A (en) |
CN (1) | CN102470109A (en) |
AR (1) | AR077546A1 (en) |
AU (1) | AU2010266342A1 (en) |
BR (1) | BRPI1015941A2 (en) |
CA (1) | CA2766067A1 (en) |
IL (1) | IL217298A0 (en) |
MX (1) | MX2012000048A (en) |
RU (1) | RU2011152105A (en) |
SG (1) | SG177309A1 (en) |
TW (1) | TW201113050A (en) |
WO (1) | WO2011002857A2 (en) |
ZA (1) | ZA201200366B (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006084058A2 (en) | 2005-02-03 | 2006-08-10 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
BRPI0618042A2 (en) | 2005-11-04 | 2011-08-16 | Wyeth Corp | uses of a rapamycin and herceptin, product, pharmaceutical package, and, pharmaceutical composition |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
ES2958968T3 (en) | 2008-06-17 | 2024-02-16 | Wyeth Llc | Antineoplastic combinations containing HKI-272 and vinorelbine |
SI2326329T1 (en) | 2008-08-04 | 2017-06-30 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
WO2010117633A1 (en) | 2009-04-06 | 2010-10-14 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer |
EP2498751B1 (en) | 2009-11-09 | 2019-04-03 | Wyeth LLC | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
FI2498756T4 (en) * | 2009-11-09 | 2023-03-22 | Tablet formulations of neratinib maleate | |
CN104447541A (en) * | 2013-09-16 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | Bosutinib compound |
CN105384686B (en) * | 2014-09-04 | 2019-07-26 | 连云港润众制药有限公司 | A kind of bosutinib method for crystallising |
WO2017175855A1 (en) * | 2016-04-08 | 2017-10-12 | Shionogi & Co., Ltd. | Stabilized solid dosage form |
KR102297116B1 (en) | 2017-03-31 | 2021-09-01 | 닛세이 에이. 에스. 비 기카이 가부시키가이샤 | plastic container |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
UA76325C2 (en) * | 2002-02-26 | 2006-07-17 | Астразенека Аб | Iressy, drug containing water-soluble cellulose derivative (variants) and method for its manufacture |
AU2004267061A1 (en) | 2003-08-19 | 2005-03-03 | Wyeth Holdings Corporation | Process for the preparation of 4-amino-3-quinolinecarbonitriles |
ES2322175T3 (en) * | 2004-09-17 | 2009-06-17 | EISAI R&D MANAGEMENT CO., LTD. | MEDICINAL COMPOSITION WITH IMPROVED STABILITY AND REDUCED GELIFICATION. |
BRPI0613574A2 (en) * | 2005-07-01 | 2016-11-16 | Wyeth Corp | isolated crystalline form of a compound, method for preparing a compound, and pharmaceutical composition |
WO2008053295A2 (en) * | 2006-10-30 | 2008-05-08 | Wockhardt Research Centre | Pharmaceutical compositions of benzoquinolizine-2-carboxylic acid |
CN101224185A (en) * | 2007-12-11 | 2008-07-23 | 山东蓝金生物工程有限公司 | Bosutinib sustained release implant for treating solid tumors |
-
2010
- 2010-06-30 RU RU2011152105/15A patent/RU2011152105A/en unknown
- 2010-06-30 BR BRPI1015941A patent/BRPI1015941A2/en not_active Application Discontinuation
- 2010-06-30 KR KR1020127002851A patent/KR20120046216A/en not_active Application Discontinuation
- 2010-06-30 CA CA2766067A patent/CA2766067A1/en not_active Abandoned
- 2010-06-30 WO PCT/US2010/040555 patent/WO2011002857A2/en active Application Filing
- 2010-06-30 CN CN2010800294791A patent/CN102470109A/en active Pending
- 2010-06-30 SG SG2011094950A patent/SG177309A1/en unknown
- 2010-06-30 MX MX2012000048A patent/MX2012000048A/en not_active Application Discontinuation
- 2010-06-30 AU AU2010266342A patent/AU2010266342A1/en not_active Abandoned
- 2010-06-30 EP EP10732568A patent/EP2448563A2/en not_active Withdrawn
- 2010-07-01 TW TW099121740A patent/TW201113050A/en unknown
- 2010-07-01 JP JP2010151063A patent/JP2011012063A/en not_active Withdrawn
- 2010-07-02 AR ARP100102373A patent/AR077546A1/en not_active Application Discontinuation
-
2011
- 2011-12-29 IL IL217298A patent/IL217298A0/en unknown
-
2012
- 2012-01-17 ZA ZA2012/00366A patent/ZA201200366B/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201113050A (en) | 2011-04-16 |
MX2012000048A (en) | 2012-01-27 |
WO2011002857A3 (en) | 2011-03-10 |
KR20120046216A (en) | 2012-05-09 |
AU2010266342A1 (en) | 2012-01-19 |
ZA201200366B (en) | 2012-10-31 |
CA2766067A1 (en) | 2011-01-06 |
RU2011152105A (en) | 2013-08-10 |
CN102470109A (en) | 2012-05-23 |
JP2011012063A (en) | 2011-01-20 |
EP2448563A2 (en) | 2012-05-09 |
WO2011002857A2 (en) | 2011-01-06 |
IL217298A0 (en) | 2012-02-29 |
AR077546A1 (en) | 2011-09-07 |
BRPI1015941A2 (en) | 2016-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG177309A1 (en) | 3-cyanoquinoline tablet formulations and uses thereof | |
AU2010316683B2 (en) | Tablet formulations of neratinib maleate | |
US9155721B2 (en) | Delayed release, oral dosage compositions that contain amorphous CDDO-Me | |
CA2409437A1 (en) | Aldosterone antagonist composition for release during aldosterone acrophase | |
TWI429437B (en) | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea | |
KR20150028367A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
US20050118256A1 (en) | Extended release alpha-2 agonist pharmaceutical dosage forms | |
US20150359795A1 (en) | High drug load pharmaceutical compositions with controllable release rate and production methods thereof | |
CN110913843B (en) | Pharmaceutical composition | |
WO2018062955A1 (en) | Lacosamide sustained release preparation | |
DK177906B1 (en) | Dispersible tablet | |
WO2023175573A1 (en) | Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor | |
WO2024028262A1 (en) | Novel formulation | |
CA3176183A1 (en) | Treatment of hypothalamic obesity | |
CN108721241A (en) | A kind of solid composite and preparation method thereof including Valsartan and Amlodipine | |
CA3029052A1 (en) | Tesofensine for reduction of body weight in prader-willi patients |